<h4>Objective</h4>This systematic review aims to evaluate the effectiveness of Tezepelumab, a monoclonal antibody targeting the thymic stromal lymphopoietin, in patients affected by chronic rhinosinusitis with nasal polyposis, both with and without comorbid asthma.<h4>Methods</h4>A systematic search of the literature was conducted across PubMed, SCOPUS, and Google Scholar databases until April 2025. Here, TSLP is linked to Nasal polyposis.